Distinctions between the islets of mice and men: implications for new therapies for type 1 and 2 diabetes

Claresa S Levetan1, Susan M Pierce

  • 1Division of Diabetes, Endocrinology and Metabolism, Chestnut Hill Hospital, Philadelphia, PA 19118, USA. ResaLevetanMD@gmail.com

Abstract

Insights

Human and rodent islets differ significantly in structure and vascularity. These key differences in islet biology may explain why diabetes treatments effective in rodents fail in human trials, highlighting the need for human-specific approaches.

Area of Science:

  • Endocrinology
  • Cell Biology
  • Regenerative Medicine

Background:

  • Diabetes treatment faces challenges despite available therapies.
  • Emerging strategies focus on pancreatic islet regeneration.

Purpose of the Study:

  • To investigate the structural and compositional differences between human and rodent islets.
  • To understand how these differences impact diabetes treatment efficacy.

Main Methods:

  • A comprehensive literature review comparing human and rodent islet characteristics.

Main Results:

  • Human islets exhibit greater cellular heterogeneity and vascularity compared to rodent islets.
  • Human islets feature unique smooth muscle-containing blood vessels absent in rodents.
  • Beta cell distribution varies, with larger human islets showing distinct patterns.

Conclusions:

  • Discrepancies in islet architecture between humans and rodents may explain the limited success of rodent-based diabetes therapies in human clinical trials.
  • Further research into human islet complexity is crucial for developing effective diabetes reversal strategies.

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...